134 related articles for article (PubMed ID: 24291969)
1. [Correlation between oral corticosteroid therapy and present disease status in myasthenia gravis].
Imai T
Rinsho Shinkeigaku; 2013; 53(11):1306-8. PubMed ID: 24291969
[TBL] [Abstract][Full Text] [Related]
2. Oral corticosteroid dosing regimen and long-term prognosis in generalised myasthenia gravis: a multicentre cross-sectional study in Japan.
Imai T; Utsugisawa K; Murai H; Tsuda E; Nagane Y; Suzuki Y; Minami N; Uzawa A; Kawaguchi N; Masuda M; Konno S; Suzuki H; Akaishi T; Aoki M
J Neurol Neurosurg Psychiatry; 2018 May; 89(5):513-517. PubMed ID: 29175893
[TBL] [Abstract][Full Text] [Related]
3. [Directions for use of corticosteroids and calcineurin inhibitors against generalized myasthenia gravis: therapeutic strategies that can lead to early improvements and veer away from high-dose oral corticosteroids].
Utsugisawa K; Nagane Y; Suzuki S; Suzuki N
Rinsho Shinkeigaku; 2012; 52(11):1047-50. PubMed ID: 23196511
[TBL] [Abstract][Full Text] [Related]
4. Oral corticosteroid therapy and present disease status in myasthenia gravis.
Imai T; Suzuki S; Tsuda E; Nagane Y; Murai H; Masuda M; Konno S; Suzuki Y; Nakane S; Fujihara K; Suzuki N; Utsugisawa K
Muscle Nerve; 2015 May; 51(5):692-6. PubMed ID: 25155615
[TBL] [Abstract][Full Text] [Related]
5. [The MG-QOL15 Japanese version: validation and associations with clinical factors].
Masuda M; Utsugisawa K; Suzuki S; Nagane Y; Ito S; Kabasawa C; Suzuki Y; Shimizu Y; Utsumi H; Fujihara K; Uchiyama S; Suzuki N
Rinsho Shinkeigaku; 2012; 52(11):1043-6. PubMed ID: 23196510
[TBL] [Abstract][Full Text] [Related]
6. The MG-QOL15 Japanese version: validation and associations with clinical factors.
Masuda M; Utsugisawa K; Suzuki S; Nagane Y; Kabasawa C; Suzuki Y; Shimizu Y; Utsumi H; Fujihara K; Uchiyama S; Suzuki N
Muscle Nerve; 2012 Aug; 46(2):166-73. PubMed ID: 22806364
[TBL] [Abstract][Full Text] [Related]
7. Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study.
Nagane Y; Murai H; Imai T; Yamamoto D; Tsuda E; Minami N; Suzuki Y; Kanai T; Uzawa A; Kawaguchi N; Masuda M; Konno S; Suzuki H; Aoki M; Utsugisawa K
BMJ Open; 2017 Feb; 7(2):e013278. PubMed ID: 28235967
[TBL] [Abstract][Full Text] [Related]
8. Less is not necessarily more: low-dose corticosteroid therapy and long-term prognosis in generalized myasthenia gravis after thymectomy.
Zhang Y; Li F; Zhu H; Yu H; Wang T; Yan X
Neurol Sci; 2022 Jun; 43(6):3949-3956. PubMed ID: 35043357
[TBL] [Abstract][Full Text] [Related]
9. Quality of life in purely ocular myasthenia in Japan.
Suzuki S; Murai H; Imai T; Nagane Y; Masuda M; Tsuda E; Konno S; Oji S; Nakane S; Motomura M; Suzuki N; Utsugisawa K
BMC Neurol; 2014 Jul; 14():142. PubMed ID: 24996227
[TBL] [Abstract][Full Text] [Related]
10. Effect of tacrolimus on soluble costimulatory molecules in patients with refractory myasthenia gravis.
Wu H; Chen L; Zhou X; Wu Y; Yan Y; Zhu Y; Zhao C; Xue Q
J Neuroimmunol; 2022 Nov; 372():577955. PubMed ID: 36054935
[TBL] [Abstract][Full Text] [Related]
11. Rationale for the clinical guidelines for myasthenia gravis in Japan.
Murai H; Utsugisawa K; Nagane Y; Suzuki S; Imai T; Motomura M
Ann N Y Acad Sci; 2018 Feb; 1413(1):35-40. PubMed ID: 29377151
[TBL] [Abstract][Full Text] [Related]
12. [Therapeutic strategies against myasthenia gravis].
Utsugisawa K; Nagane Y
Nihon Rinsho; 2013 May; 71(5):881-6. PubMed ID: 23777099
[TBL] [Abstract][Full Text] [Related]
13. [Clinical factors affecting quality of life and treatment targets in patients with myasthenia gravis].
Nagane Y
Rinsho Shinkeigaku; 2013; 53(11):1299-302. PubMed ID: 24291967
[TBL] [Abstract][Full Text] [Related]
14. Comparison of quality of life and activity of daily living status of patients with myasthenia gravis treated with low-dose and high-dose prednisolone.
Katsuki M; Sugahara H; Kojima Y; Yamashita K; Moriuchi H; Kubota T; Masuda M; Irikura M
Neuro Endocrinol Lett; 2020 Oct; 41(4):173-178. PubMed ID: 33307652
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality-of-life and treatment targets in myasthenia gravis.
Utsugisawa K; Suzuki S; Nagane Y; Masuda M; Murai H; Imai T; Tsuda E; Konno S; Nakane S; Suzuki Y; Fujihara K; Suzuki N
Muscle Nerve; 2014 Oct; 50(4):493-500. PubMed ID: 24536040
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of pure ocular myasthenia: a proposal from Japan MG registry 2012].
Suzuki S
Rinsho Shinkeigaku; 2013; 53(11):1303-5. PubMed ID: 24291968
[TBL] [Abstract][Full Text] [Related]
17. Does perioperative high-dose prednisolone have clinical benefits for generalized myasthenia gravis?
Sekine Y; Kawaguchi N; Hamada C; Sekiguchi H; Yasufuku K; Iyoda A; Shibuya K; Fujisawa T
Eur J Cardiothorac Surg; 2006 Jun; 29(6):908-13. PubMed ID: 16675232
[TBL] [Abstract][Full Text] [Related]
18. Clinical features and treatment status of antiacetylcholine receptor antibody-positive ocular myasthenia gravis.
Isshiki Y; Mimura O; Gomi F
Jpn J Ophthalmol; 2020 Nov; 64(6):628-634. PubMed ID: 32936398
[TBL] [Abstract][Full Text] [Related]
19. Reappraisal of Oral Steroid Therapy for Myasthenia Gravis.
Imai T; Suzuki S; Nagane Y; Uzawa A; Murai H; Utsugisawa K
Front Neurol; 2020; 11():868. PubMed ID: 32982912
[TBL] [Abstract][Full Text] [Related]
20. Reduced quality of life in myasthenia gravis patients: A study on 185 patients from China.
Wu X; Li RY; Ye XB; Wang N
Front Neurol; 2022; 13():1072861. PubMed ID: 36712441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
